tetano
Editor, Senior Moderator
Am J Transplant
. 2021 Apr 17.
doi: 10.1111/ajt.16607. Online ahead of print.
Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients
Smaragdi Marinaki[SUP] 1 [/SUP], Stamatis Adamopoulos[SUP] 2 [/SUP], Dimitrios Degiannis[SUP] 3 [/SUP], Sotirios Roussos[SUP] 4 [/SUP], Ioanna D Pavlopoulou[SUP] 5 [/SUP], Angelos Hatzakis[SUP] 6 [/SUP], Ioannis N Boletis[SUP] 1 [/SUP]
Affiliations
Abstract
Solid organ transplant (SOT) recipients represent a high-risk group for all SARS-COV-2 infection-related adverse outcomes. Therefore, most European countries have established prioritization of SOTrecipients in their vaccination programs. Suboptimal vaccine efficacy to the SARS-COV-2 vaccines is anticipated; however, they have been excluded from vaccination trials. Overall response rates to other vaccines as influenza have demonstrated high, though acceptable, variability.
. 2021 Apr 17.
doi: 10.1111/ajt.16607. Online ahead of print.
Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients
Smaragdi Marinaki[SUP] 1 [/SUP], Stamatis Adamopoulos[SUP] 2 [/SUP], Dimitrios Degiannis[SUP] 3 [/SUP], Sotirios Roussos[SUP] 4 [/SUP], Ioanna D Pavlopoulou[SUP] 5 [/SUP], Angelos Hatzakis[SUP] 6 [/SUP], Ioannis N Boletis[SUP] 1 [/SUP]
Affiliations
- PMID: 33864722
- DOI: 10.1111/ajt.16607
Abstract
Solid organ transplant (SOT) recipients represent a high-risk group for all SARS-COV-2 infection-related adverse outcomes. Therefore, most European countries have established prioritization of SOTrecipients in their vaccination programs. Suboptimal vaccine efficacy to the SARS-COV-2 vaccines is anticipated; however, they have been excluded from vaccination trials. Overall response rates to other vaccines as influenza have demonstrated high, though acceptable, variability.